. 2022 Oct 25;39(12):805–812. doi: 10.1002/da.23287

Table 2.

Incidence of psychopharmacological treatment

	Baseline		Total
	AAS users (%)	Control (%)	AAS users	Control	HR	p Value	HR adjusted	p Value
At least one prescription of antipsychotics	5.9	3.5	15.6	7.3	2.69 (1.99−3.63)	<.0001^a	2.22 (1.63−3.03)	<.0001^a
At least one prescription of anxiolytics	5.1	3.6	11.6	6.4	2.34 (1.62−3.38)	<.0001^a	2.27 (1.56−3.31)	<.0001^a
At least one prescription of antidepressants	13.8	8.3	26.2	16.3	1.65 (1.28−2.13)	.0001^a	1.44 (1.11−1.87)	.006^a
At least one prescription of psychostimulants	2.4	2.0	6.8	3.9	2.29 (1.47−3.57)	.0002^a	1.86 (1.19−2.93)	.007^a

Note: Baseline: The cumulative prevalence at baseline, total: The cumulative prevalence for the entire period of investigation (baseline plus follow‐up).

Abbreviation: AAS, anabolic androgenic steroid.

^{^a}

Significant p value. Data were analyzed with time to event analysis (a Cox proportional hazard regression model).